RP
Therapeutic Areas
Neurogene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NGN-401 | Rett Syndrome | Phase 1/2 & Registrational |
Leadership Team at Neurogene
RM
Rachel McMinn, Ph.D.
Founder and Chief Executive Officer
CM
Christine Mikail, J.D.
President and Chief Financial Officer
SC
Stuart Cobb, Ph.D.
Chief Scientific Officer
JJ
Julie Jordan, M.D.
Chief Medical Officer
AM
Andrew Mulberg, M.D.
SVP, Regulatory Affairs, QA, QC
DM
Donna M. Cochener, J.D., LL.M.
SVP and General Counsel
RB
Robert Baffi, Ph.D.
Venture Partner, Board Member
CF
Cory Freedland, Ph.D.
Partner, Board Member
KW
Keith Woods
Chief Operating Officer, Board Member